Retatrutide appears to be a new pharmaceutical in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By activating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ul